Prognoz qilingan narxning foydaga nisbati: NeuroSense Therapeutics Ltd. (NRSN)
NeuroSense Therapeutics jamoasi yetakchi neyrobiologlarning tajribasidan foydalanib, ixtisoslashgan tadqiqot koordinatorlarini faol jalb qilmoqda. NeuroSense Therapeutics neyronlarga keng qamrovli ta'sir ko'rsatish orqali falajlikni sekinlashtiruvchi ALS ga qarshi innovatsion dori vositasi — PrimeC ni ishlab chiqmoqda. Biroq, sanoatning texnologik gigantlariga qarshi raqobatbardosh poygada klinik sinovlarning muvaffaqiyatsiz tugash xavfi yuqori bo'lib qolmoqda. GURU.Markets platformasida kompaniyaning kelajakdagi P/E koeffitsiyenti pul oqimini aniq vizuallashtiradi, bunda 0.00 darajasi parametrning holatini ko'rsatadi.
NeuroSense Therapeutics, Ltd. (NRSN) kompaniyasining tahliliy kesimlari va maʼlumotlar hisoboti
- kotirovkalar va tahlilchilar prognozi:
- kompaniyaning birjadagi kapitallashuv ko'rsatkichlari:
- emitentning balans qiymati statistikasi:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning xususiy kapitalga nisbati NeuroSense Therapeutics|NRSN - Uzoq muddatli qarzdorlikning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati NeuroSense Therapeutics|NRSN - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans kapitallashuviga nisbati NeuroSense Therapeutics Ltd|NRSN - Kompaniyaning uzoq muddatli qarzdorligi|Kompaniyaning qisqa muddatli qarzi NeuroSense Therapeutics|Tezkor likvidlik koeffitsiyenti neurosense-tx.com
- kompaniyaning daromadliligi va baholash multiplikatorlari ko'rsatkichlari:
NRSN - Kompaniyaning sof daromadi|Kelajakdagi foyda NeuroSense Therapeutics|NRSN - Kompaniya qiymatining sof foydaga nisbati|Prognoz qilingan narxning foydaga nisbati NeuroSense Therapeutics|NRSN - Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|EV/EBITDA multiplikatori NeuroSense Therapeutics Ltd|NRSN - Foizlar, soliqlar va amortizatsiya chegirilmasdan oldingi daromad|Bir aksiya uchun sof foyda (EPS TTM) NeuroSense Therapeutics|NRSN - So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda|So'nggi o'n ikki oy davomida bir aksiya uchun foydaning yillik o'sishi neurosense-tx.com|NRSN - Joriy yilda bir aksiya uchun foyda ortishi|Keyingi yil uchun foyda o'sishi prognozi NeuroSense Therapeutics
Kompaniyaning barcha koʻrsatkichlari tahlili:NRSN NeuroSense Therapeutics Ltd.
O'sish aktivlarini tanlashda xavflarni minimallashtirish uchun joriy kapitalizatsiyaning kutilayotgan foyda miqdoriga nisbatini hisobga olgan holda bozor kutuvlarini baholash zarur. NeuroSense Therapeutics (NRSN) kompaniyasining forward P/E ko'rsatkichini tahlil qilish boshqaruvning haddan tashqari yuqori baholanganini aniqlash imkonini beradi, bu esa NeuroSense Therapeutics (NRSN) uchun juda muhimdir, chunki biznesning kelgusidagi qiymati bevosita ALS dori vositalari uchun klinik sinovlarning muvaffaqiyatiga va R&D moliyalashtirish hajmiga bog'liq.
NeuroSense Therapeutics kimlar bilan raqobatlashadi
Forvard P/E multiplikatori BIIB|NBIX - Prognoz qilingan narx-foyda nisbati|Regencell - Prognoz qilingan narxning foydaga nisbati|Forvard P/E multiplikatori Axsome Corp AXSM|ACAD - Kelajakdagi narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori XENE (xenon-pharma.com)|Viking Therapeutics, Inc. (VKTX) - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati Supernus Pharmaceuticals, Inc. (SUPN)|Kelajakdagi narxning foydaga nisbati Catalyst Pharmaceuticals Inc|Denali Corp (DNLI) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Forvard P/E multiplikatori HRMY|BHVN - Prognoz qilingan narx-foyda nisbati|Kelajakdagi narxning foydaga nisbati Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Narxning kelajakdagi foydaga nisbati|PRAX - Kelajakdagi narxning foydaga nisbati|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Anavex Life Sciences Corp AVXL|CBLL: Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Prothena (PRTA)|Prognoz qilingan narxning foydaga nisbati ALEC|ANNX: Kelajakdagi narx-foyda multiplikatori|Prognoz qilingan narxning foydaga nisbati OMER (Omeros Corporation)|Kapitalizatsiyaning kelajakdagi foydaga nisbati NGNE|Forvard P/E multiplikatori ACIU (AC Immune)|Kelajakdagi narx-foyda multiplikatori VYGR|Neumora Therapeutics, Inc. - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Scilex Holding|Tevogen Bio Holdings, Inc. (TVGN) - Kelajakdagi narxning foydaga nisbati|Alpha Cognition Inc. - Kelajakdagi narx-foyda multiplikatori|CGTX (Cognition Therapeutics) - Forvard P/E multiplikatori|Forvard P/E multiplikatori inhibikase.com|Kelajakdagi narxning foydaga nisbati Cassava Sciences (SAVA)|ASRT: Narxning kutilayotgan foydaga nisbati|Forvard P/E multiplikatori COYA (Coya Therapeutics)|VistaGen Therapeutics, Inc. (VTGN) - Prognoz qilingan narx-foyda nisbati|OVID: Prognoz qilingan narxning foydaga nisbati|ABOS - Forvard P/E multiplikatori|CRVO (CervoMed) - Prognoz qilingan narxning foydaga nisbati|ATHE: Kapitalizatsiyaning kelajakdagi foydaga nisbati|CLNN (Clene Inc) - Forvard P/E multiplikatori|PepGen Corp (PEPG) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Forvard P/E multiplikatori JUNS|Prognoz qilingan narxning foydaga nisbati relmada.com RLMD|Kelajakdagi narxning foydaga nisbati Annovis Bio ANVS|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Grace Therapeutics Inc (GRCE)|AIFF - Kelajakdagi narxning foydaga nisbati|KLTO (Klotho Neurosciences Inc) - Narxning kelajakdagi foydaga nisbati|Reviva Pharmaceuticals (RVPH) - Kelajakdagi narxning foydaga nisbati|MetaVia - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati NeurAxis|Helius Medical Technologies Inc. (HSDT) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Passage Bio, Inc. (PASG)|bionomics.com.au - Narxning kelajakdagi foydaga nisbati|Kelajakdagi narxning foydaga nisbati Minerva Neurosciences NERV|ATHA: Narxning kelajakdagi foydaga nisbati|Addex Therapeutics Ltd - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Alzamend Neuro, Inc.|CYCN (cyclerion.com) - Prognoz qilingan narxning foydaga nisbati|Protagenic Therapeutics, Inc. (PTIX) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Pasithea Therapeutics Corp|CRGT: Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Avenue Therapeutics, Inc. (ATXI)|BCLI - Prognoz qilingan narx-foyda nisbati|Kelajakdagi narxning foydaga nisbati Cara Therapeutics, Inc CARA|CHRO: Narxning kelajakdagi foydaga nisbati|Eliem - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Intra-Cellular Therapies|LBPH (Longboard Pharmaceuticals, Inc.) - Prognoz qilingan narxning foydaga nisbati|Marinus Pharmaceuticals Inc (MRNS) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati NKGen|NRBO: Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Sage Therapeutics, Inc. (SAGE)|SNPX - Prognoz qilingan narx-foyda nisbati|Kelajakdagi narxning foydaga nisbati Trevena TRVN|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Vigil Neuroscience Inc. (VIGL)|Anew Medical - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Cerevel Corp
